Publications by authors named "Andrew J Armstrong"

100Publications

Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial.

Eur Urol 2020 Sep 9;78(3):347-357. Epub 2020 Jun 9.

Hematology/Medical Oncology, OHSU Knight Cancer Institute Oregon Health & Science University, Portland, OR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2020.04.061DOI Listing
September 2020

PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma.

Clin Genitourin Cancer 2020 Apr 10. Epub 2020 Apr 10.

Department of Medicine, School of Medicine, Duke University, Durham, NC; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2020.03.020DOI Listing
April 2020

Surface engineering for efficient capture of circulating tumor cells in renal cell carcinoma: From nanoscale analysis to clinical application.

Biosens Bioelectron 2020 Aug 1;162:112250. Epub 2020 May 1.

Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin, Madison, Madison, WI, 53705, USA; Yonsei Frontier Lab and Department of Pharmacy, Yonsei University, Seoul, 03722, South Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bios.2020.112250DOI Listing
August 2020

Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations.

Prostate Cancer Prostatic Dis 2020 09 5;23(3):381-397. Epub 2020 Mar 5.

Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41391-020-0217-3DOI Listing
September 2020

Androgen receptor variant-driven prostate cancer II: advances in clinical investigation.

Prostate Cancer Prostatic Dis 2020 09 24;23(3):367-380. Epub 2020 Feb 24.

Departments of Medicine, Surgery, and Pharmacology and Cancer Biology, Divisions of Medical Oncology and Urology, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41391-020-0215-5DOI Listing
September 2020

Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial.

Eur Urol Oncol 2020 Feb 13. Epub 2020 Feb 13.

Department of Medicine, Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA; Department of Surgery, Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA; Department of Pharmacology, Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA; Department of Cancer Biology, Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2020.01.005DOI Listing
February 2020

Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape.

Cancer J 2020 Jan/Feb;26(1):64-75

Divisions of Medical Oncology and Urology, Duke Cancer Institute, Durham, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000418DOI Listing
January 2020

Has Mismatch Repair-Deficient Cancer Met Its MATCH?

J Clin Oncol 2020 01 3;38(3):183-187. Epub 2019 Dec 3.

Duke Cancer Institute, Center for Prostate and Urologic Cancers, Duke University, Durham, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.02860DOI Listing
January 2020

Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer.

Urol Oncol 2020 03 12;38(3):79.e15-79.e22. Epub 2019 Sep 12.

Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC; Department of Medicine/Division of Medical Oncology, Duke University, Durham, NC; Department of Surgery/Division of Urology, Duke University, Durham, NC. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2019.08.015DOI Listing
March 2020

Molecular determinants for enzalutamide-induced transcription in prostate cancer.

Nucleic Acids Res 2019 11;47(19):10104-10114

Department of Pathology, Duke University School of Medicine, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/nar/gkz790DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821169PMC
November 2019

Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.

Prostate 2019 11 9;79(15):1752-1761. Epub 2019 Sep 9.

Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.23899DOI Listing
November 2019

Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer.

Urol Oncol 2019 11 19;37(11):813.e1-813.e9. Epub 2019 Jul 19.

Department of Medicine, School of Medicine, Duke University, Durham, NC; Duke Cancer Institute Center for Prostate and Urologic Cancer, Durham, NC; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2019.06.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823135PMC
November 2019

Reply to L. Dirix, B. De Laere et al, and A. Sharp et al.

J Clin Oncol 2019 08 2;37(24):2184-2186. Epub 2019 Jul 2.

Andrew J. Armstrong, MD, ScM and Susan Halabi, PhD, Duke University, Durham, NC; Jun Luo, PhD, Johns Hopkins University, Baltimore, MD; David M. Nanus, MD, Weill Cornell Medical College, New York, NY; Howard I. Scher, MD, Memorial Sloan Kettering Cancer Center, New York, NY; Emmanuel S. Antonarakis, MD, Johns Hopkins University, Baltimore, MD; and Daniel J. George, MD, Duke University, Durham, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.01230DOI Listing
August 2019

Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer.

Prostate 2019 07 2;79(10):1106-1116. Epub 2019 May 2.

Department of Medicine and Surgery, Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.23822DOI Listing
July 2019

Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials.

Prostate Cancer Prostatic Dis 2019 12 29;22(4):522-530. Epub 2019 Apr 29.

Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41391-019-0151-4
Publisher Site
http://dx.doi.org/10.1038/s41391-019-0151-4DOI Listing
December 2019

Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients.

Prostate Cancer Prostatic Dis 2019 12 12;22(4):588-592. Epub 2019 Apr 12.

Division of Medical Oncology, Departments of Medicine, Duke Prostate and Urologic Cancer Center, Duke University and the Duke Cancer Institute, Durham, NC, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41391-019-0144-3
Publisher Site
http://dx.doi.org/10.1038/s41391-019-0144-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853838PMC
December 2019

Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma.

Clin Genitourin Cancer 2019 06 5;17(3):e513-e521. Epub 2019 Feb 5.

Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, Durham, NC. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15587673193004
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2019.01.017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004481PMC
June 2019

Injuries involving the central tarsal bone in nonracing dogs: Short-term outcomes and prognostic factors.

Vet Surg 2019 May 28;48(4):524-536. Epub 2019 Feb 28.

Veterinary Medical Center, Michigan State University, East Lansing, Michigan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/vsu.13187DOI Listing
May 2019

The promise of immunotherapy in genitourinary malignancies.

Precis Clin Med 2018 Dec 19;1(3):97-101. Epub 2018 Dec 19.

Duke Cancer Institute, Duke University School of Medicine, Durham, NC.

View Article

Download full-text PDF

Source
https://academic.oup.com/pcm/article/1/3/97/5253459
Publisher Site
http://dx.doi.org/10.1093/pcmedi/pby018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333044PMC
December 2018

Assessing the Prognostic Value of the Automated Bone Scan Index for Prostate Cancer-Reply.

JAMA Oncol 2019 02;5(2):270-271

Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2018.5874DOI Listing
February 2019

Updates in advanced prostate cancer 2018.

Prostate Cancer Prostatic Dis 2018 11 2;21(4):449-450. Epub 2018 Oct 2.

Duke Cancer Institute, Divisions of Medical Oncology and Urology, Duke University, DUMC Box 103861, Durham, NC, 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41391-018-0100-7DOI Listing
November 2018

Precision Medicine Approaches When Prostate Cancer Akts Up.

Clin Cancer Res 2019 02 11;25(3):901-903. Epub 2018 Sep 11.

Duke Cancer Institute and the Duke Prostate and Urologic Cancer Center, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-2491DOI Listing
February 2019

Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer?

Prostate Cancer Prostatic Dis 2018 09 1;21(3):419-430. Epub 2018 Jun 1.

Department of Medicine, School of Medicine, Duke University, Durham, NC, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41391-018-0049-6
Publisher Site
http://dx.doi.org/10.1038/s41391-018-0049-6DOI Listing
September 2018

Clinical utility of non-EpCAM based circulating tumor cell assays.

Adv Drug Deliv Rev 2018 02 31;125:132-142. Epub 2018 Jan 31.

Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, Duke University Medical Center, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.addr.2018.01.013DOI Listing
February 2018

The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.

Prostate Cancer Prostatic Dis 2018 09 20;21(3):306-318. Epub 2017 Dec 20.

Duke University Medical Center and Cancer Institute, Duke Prostate and Urologic Cancer Center, Durham, NC, 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41391-017-0014-9DOI Listing
September 2018

The Who, What, and How of Cabazitaxel Treatment in Metastatic Castration-Resistant Prostate Cancer.

J Clin Oncol 2017 10 15;35(28):3175-3177. Epub 2017 Aug 15.

Tian Zhang and Andrew J. Armstrong, Duke Cancer Institute, Durham NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.7931DOI Listing
October 2017

Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer.

Clin Genitourin Cancer 2017 12 14;15(6):e1137-e1141. Epub 2017 Jul 14.

Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, Duke University Medical Center, Durham, NC. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2017.07.005DOI Listing
December 2017

Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo.

J Urol 2017 12 20;198(6):1324-1332. Epub 2017 Jul 20.

Oregon Health & Science University Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2017.07.071DOI Listing
December 2017

Exploiting DNA damage without repair: The activity of platinum chemotherapy in BRCA-mutated prostate cancers.

Cancer 2017 09 13;123(18):3441-3444. Epub 2017 Jun 13.

Duke Cancer Institute, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.30806
Publisher Site
http://dx.doi.org/10.1002/cncr.30806DOI Listing
September 2017

RECISTing the Temptation to Prematurely Stop Nivolumab.

Eur Urol 2017 09 25;72(3):377-378. Epub 2017 Apr 25.

Departments of Medicine and Surgery, Pharmacology, and Cancer Biology, Divisions of Medical Oncology and Urology, Duke Cancer Institute, Durham, NC, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2017.04.021DOI Listing
September 2017

Prognostic and predictive biomarkers in metastatic castration-resistant prostate cancer.

Clin Adv Hematol Oncol 2017 Mar;15(3):184-188

Duke Cancer Institute, Duke University, Durham, North Carolina.

View Article

Download full-text PDF

Source
March 2017

Drug development in prostate cancer: time to embrace RECIST?

Lancet Oncol 2017 04 8;18(4):419-421. Epub 2017 Mar 8.

Duke Cancer Institute, Division of Medical Oncology, Department of Medicine, Durham, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30149-3DOI Listing
April 2017

Reply to M.A.N. Şendur et al and J. Michels.

J Clin Oncol 2017 01 31;35(1):123. Epub 2016 Oct 31.

David F. Penson, Vanderbilt University and the VA Tennessee Valley Geriatric Research, Education, and Clinical Center, Nashville, TN; Andrew J. Armstrong, Duke University, Durham, NC; Raoul Concepcion, Urology Associates PC, Nashville, TN; Neeraj Agarwal, University of Utah, Salt Lake City, UT; Carl Olsson, Icahn School of Medicine at Mount Sinai, New York, NY; Lawrence Karsh, The Urology Center of Colorado, Denver, CO; Curtis Dunshee, Urological Associates of Southern Arizona, Tucson, AZ; Fong Wang and Kenneth Wu, Medivation, San Francisco, CA; Andrew Krivoshik, Astellas Pharma Global Development, Northbrook, IL; De Phung, Astellas Pharma Global Development, Leiden, Netherlands; and Celestia S. Higano, University of Washington, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.9371DOI Listing
January 2017

Predictive medicine: Using circulating biomarkers to guide management of patients with genitourinary cancers.

Urol Oncol 2016 11 26;34(11):488-489. Epub 2016 Oct 26.

Duke Cancer Institute, Durham, NC. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2016.09.009DOI Listing
November 2016

Treatment-related neuroendocrine prostate cancer resulting in Cushing's syndrome.

Int J Urol 2016 12 21;23(12):1038-1041. Epub 2016 Oct 21.

Department of Medicine, Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/iju.13225DOI Listing
December 2016

Magnetic separation of acoustically focused cancer cells from blood for magnetographic templating and analysis.

Lab Chip 2016 09;16(19):3833-3844

NSF Research Triangle Materials Research Science and Engineering Center, Duke University, Durham, NC 27708, USA and Department of Biomedical Engineering, Duke University, Durham, NC 27708, USA and Department of Mechanical Engineering and Materials Science, Duke University, Durham, NC 27708, USA and Department of Chemical and Biological Engineering, University of New Mexico, Albuquerque, NM 87131, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1039/c6lc00719hDOI Listing
September 2016

Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer.

Clin Cancer Res 2017 Mar 6;23(5):1346-1357. Epub 2016 Sep 6.

Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-1211DOI Listing
March 2017

Mesenchymal-Epithelial Transition in Sarcomas Is Controlled by the Combinatorial Expression of MicroRNA 200s and GRHL2.

Mol Cell Biol 2016 10 12;36(19):2503-13. Epub 2016 Sep 12.

Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA Program in Molecular Genetics and Genomics, Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/MCB.00373-16DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021378PMC
October 2016

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.

J Clin Oncol 2016 05 7;34(14):1652-9. Epub 2016 Mar 7.

Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.65.7270
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.65.7270DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872320PMC
May 2016

Development of a Novel c-MET-Based CTC Detection Platform.

Mol Cancer Res 2016 06 7;14(6):539-47. Epub 2016 Mar 7.

Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, Duke University, Durham, North Carolina. Department of Pharmacology and Cancer Biology, Duke University, Durham, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-16-0011DOI Listing
June 2016

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

J Clin Oncol 2016 Apr 22;34(12):1402-18. Epub 2016 Feb 22.

Howard I. Scher, Michael J. Morris, Dana E. Rathkopf, and Susan F. Slovin, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College; David Nanus, NewYork Presbyterian Weill Cornell Medical Center; Lawrence W. Schwartz, NewYork Presbyterian Columbia University Medical Center, New York, NY; Walter M. Stadler, University of Chicago Medicine, Chicago, IL; Celestina Higano and Peter S. Nelson, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA; Ethan Basch, University of North Carolina at Chapel Hill, Chapel Hill, NC; Emmanual S. Antonarakis and Michael A. Carducci, Johns Hopkins University School of Medicine, Baltimore, MD; Tomasz M. Beer, Oregon Health and Science University, Portland, OR; Paul G. Corn and Christopher Logothetis, MD Anderson Cancer Center, Houston, TX; Robert Dreicer, University of Virginia School of Medicine, Charlottesville, VA; Daniel J. George, Susan Halabi, and Andrew J. Armstrong, Duke University and Duke Cancer Institute, Durham, NC; Elisabeth I. Heath, Wayne State University Karmanos Cancer Institute, Detroit; and Maha Hussain, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Wm. Kevin Kelly, Sidney Kimmel School of Medicine at Thomas Jefferson University, Philadelphia, PA; Glenn Liu and George Wilding, University of Wisconsin Carbone Cancer Center, Madison, WI; Mark N. Stein, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ; Charles S. Ryan and Eric J. Small, University of California Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Oliver Sartor, Tulane School of Medicine, New Orleans, LA; Matthew Raymond Smith, Massachusetts General Hospital Cancer Center and Harvard Medical School; Mary-Ellen Taplin and Philip W. Kantoff, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, Franc

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.2702DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872347PMC
April 2016

Tasquinimod in the treatment of castrate-resistant prostate cancer - current status and future prospects.

Ther Adv Urol 2016 Feb;8(1):9-18

Associate Professor of Medicine and Surgery, Associate Director for Clinical Research in Genitourinary Oncology, Duke Cancer Institute, Divisions of Medical Oncology and Urology, Duke University, DUMC Box 103861, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1756287215603558DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4707420PMC
February 2016

Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.

J Clin Oncol 2016 06 25;34(18):2098-106. Epub 2016 Jan 25.

David F. Penson, Vanderbilt University Medical Center and Tennessee Valley Veterans Administration Medical Center Geriatric Research, Education, and Clinical Center; Raoul Concepcion, Urology Associates PC, Nashville, TN; Andrew J. Armstrong, Duke Cancer Institute, Duke University, Durham, NC; Neeraj Agarwal, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Carl Olsson, Icahn School of Medicine at Mount Sinai, New York, NY; Lawrence Karsh, The Urology Center of Colorado, Denver, CO; Curtis Dunshee, Urological Associates of Southern Arizona, Tucson, AZ; Fong Wang and Kenneth Wu, Medivation, San Francisco, CA; Andrew Krivoshik, Astellas Pharma Global Development, Northbrook, IL; De Phung, Astellas Pharma Global Development, Leiden, The Netherlands; and Celestia S. Higano, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.9285DOI Listing
June 2016

Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer.

Curr Oncol Rep 2016 Jan;18(1)

Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, Duke University Medical Center DUMC 103861, Durham, NC, 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-015-0490-9DOI Listing
January 2016

Management of Prostate Cancer in the Elderly.

Clin Geriatr Med 2016 Feb 14;32(1):113-32. Epub 2015 Oct 14.

Department of Medical Oncology, Duke University Medical Center, DUMC Box 103861, Durham, NC 27710, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cger.2015.08.001DOI Listing
February 2016

Docetaxel Resistance in Prostate Cancer: Taking It Up a Notch.

Clin Cancer Res 2015 Oct 25;21(20):4505-7. Epub 2015 Aug 25.

Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina. Division of Urology, Department of Surgery, Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-15-1613DOI Listing
October 2015

Using circulating tumor cells to inform on prostate cancer biology and clinical utility.

Crit Rev Clin Lab Sci 2015 16;52(4):191-210. Epub 2015 Jun 16.

a Duke Cancer Institute, Duke University Medical Center , Durham , NC , USA .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10408363.2015.1023430DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808585PMC
May 2016

Docetaxel for advanced prostate cancer: how early to start?

Lancet Oncol 2015 Jul 28;16(7):741-2. Epub 2015 May 28.

DUMC Box 103861, Duke Cancer Institute, Divisions of Medical Oncology and Urology, Duke University, Durham, NC 27710, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(15)00012-1DOI Listing
July 2015

New treatment options in castration-resistant prostate cancer.

J Natl Compr Canc Netw 2015 May;13(5 Suppl):690-3

Presented by Andrew J. Armstrong, MD, ScM, Associate Professor of Medicine, Co-Director of Clinical Research Program, Duke Cancer Institute, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2015.0205DOI Listing
May 2015

Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.

Clin Genitourin Cancer 2015 Aug 24;13(4):392-399. Epub 2015 Jan 24.

Duke Cancer Institute, Divisions of Medical Oncology and Urology, Departments of Medicine and Surgery, Duke University Medical Center, Durham, NC. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2015.01.004DOI Listing
August 2015

Making progress on progression in metastatic prostate cancer.

J Clin Oncol 2015 Apr 9;33(12):1322-4. Epub 2015 Feb 9.

Alliance Statistics and Data Center, Duke University, Durham, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.4283DOI Listing
April 2015

Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.

Urol Oncol 2015 Mar 13;33(3):110.e1-9. Epub 2015 Jan 13.

Department of Medicine, Duke University Medical Center, Durham, NC; Duke Cancer Institute, Duke University Medical Center, Durham, NC. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10781439140031
Publisher Site
http://dx.doi.org/10.1016/j.urolonc.2014.09.002DOI Listing
March 2015

Carcinosarcomas: tumors in transition?

Histol Histopathol 2015 Jun 12;30(6):673-87. Epub 2015 Jan 12.

Center for RNA Biology, and Department of Molecular Genetics and Microbiology, Program in Cancer Genetics and Genomics, Duke Cancer Institute, Duke University Medical Center; Durham, NC, and Department of Biochemistry and Molecular Biology, The University of Texas Medical Center, Galveston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14670/HH-30.673DOI Listing
June 2015

Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.

Expert Opin Pharmacother 2015 Mar 23;16(4):473-85. Epub 2014 Dec 23.

Duke Cancer Institute, Duke University Medical Center, Division of Medical Oncology, Department of Medicine , DUMC 3841, Durham, NC 27710 , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.2015.995090DOI Listing
March 2015

In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet.

Oncology (Williston Park) 2014 Oct;28(10):881, 883

View Article

Download full-text PDF

Source
October 2014

Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).

Urol Oncol 2014 Nov 16;32(8):1308-16. Epub 2014 Sep 16.

Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2014.08.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341998PMC
November 2014